---
title: "Theriva sells ribaxamase for $350,000 upfront and hands $140,000 to PREV"
url: "https://aibio.space/news/theriva-sells-ribaxamase-350000-upfront-hands-140000-prev/"
event_date: "2026-11-02"
date_published: "2026-11-05"
description: "Biossil Labs takes over SYN-004 and its costs, but Theriva's larger payments depend on approvals and sales, and a share goes to PREV ABR LLC."
---

# Theriva sells ribaxamase for $350,000 upfront and hands $140,000 to PREV

Theriva Biologics (NYSE American: TOVX) sold its antibiotic-degrading enzyme portfolio, led by SYN-004 (ribaxamase), to Toronto-based Biossil Labs Inc. on October 30 for a $350,000 upfront payment. Steven A. Shallcross, Chief Executive Officer and Chief Financial Officer, signed the filing. The sale sheds a program Theriva said in August it could not afford to finish, but brings in little cash. At closing Theriva paid $140,000 to PREV ABR LLC, its counterparty in a November 7, 2012 asset purchase agreement that sets payments owed to PREV on these assets, and every larger payment depends on Biossil winning approvals and selling product. In Theriva's favor, Biossil assumed all future development and commercialization costs, the release says. [November 2 filing](https://www.sec.gov/Archives/edgar/data/894158/000110465926121318/tm2628598d1_8k.htm) · [November 2 release](https://www.sec.gov/Archives/edgar/data/894158/000110465926121318/tm2628598d1_ex99-1.htm)

## What Theriva can actually collect

Beyond the non-refundable upfront, Theriva can receive up to $3 million in regulatory milestones tied to the first FDA approval and first European Medicines Agency marketing authorization of any product. Up to $88 million in sales milestones turn on cumulative worldwide net sales thresholds that the filed agreement redacts. A low-single-digit royalty on net sales of ribaxamase, SYN-006 and derived products is capped at $250 million. A low-double-digit share of any license consideration Biossil collects sits outside that cap. The filing warns: "There can be no assurance that any milestone will be achieved, that any product will be approved or commercialized, or that the Company will receive any payments beyond the upfront payment." [November 2 filing](https://www.sec.gov/Archives/edgar/data/894158/000110465926121318/tm2628598d1_8k.htm) · [Purchase agreement](https://www.sec.gov/Archives/edgar/data/894158/000110465926121318/tm2628598d1_ex10-1.htm)

Theriva would keep less than the headline figures. Under the amended PREV agreement, Theriva must pass on 50% of milestone payments, a third of royalties and 50% of license consideration, up to an aggregate cap of $13.0 million that includes the $140,000 closing payment. Biossil may offset finally determined indemnification amounts against future payments, though not against the upfront. The agreement lists Blank Rome LLP as Theriva's counsel and names no financial advisor for either side or counsel for Biossil; it states that no broker, finder or financial advisor is owed a fee from Biossil through an arrangement by Theriva. Anthony Mouchantaf signed for Biossil as chief executive. [November 2 filing](https://www.sec.gov/Archives/edgar/data/894158/000110465926121318/tm2628598d1_8k.htm) · [Purchase agreement](https://www.sec.gov/Archives/edgar/data/894158/000110465926121318/tm2628598d1_ex10-1.htm) · [November 2 release](https://www.sec.gov/Archives/edgar/data/894158/000110465926121318/tm2628598d1_ex99-1.htm)

## A program that stalled before the hard test

Theriva points to a completed Phase 2b trial in 412 patients on intravenous ceftriaxone, in which it says ribaxamase protected the gut microbiome and lowered the incidence of Clostridioides difficile infection. The Phase 1b/2a trial at Washington University in allogeneic transplant recipients, planned for up to 36 evaluable participants, paused enrollment after 2 of 3 cohorts. The finished cohorts used meropenem, which SYN-004 does not metabolize, and piperacillin, which it does metabolize but which tazobactam protects. The third cohort, on cefepime, a substrate for SYN-004, was meant to test the enzyme fully. Theriva's August quarterly filing said its cash would not cover that last cohort. Biossil now controls the trial and owes only commercially reasonable efforts toward approval of at least one product. [November 2 release](https://www.sec.gov/Archives/edgar/data/894158/000110465926121318/tm2628598d1_ex99-1.htm) · [August 11 quarterly filing](https://www.sec.gov/Archives/edgar/data/894158/000110465926093786/tmb-20260630x10q.htm) · [Purchase agreement](https://www.sec.gov/Archives/edgar/data/894158/000110465926121318/tm2628598d1_ex10-1.htm)

It is the second legacy asset Theriva has let go this year for a small upfront: in February it licensed SYN-020 to Rasayana Therapeutics for $300,000 upfront plus milestones. [February 18 filing](https://www.sec.gov/Archives/edgar/data/894158/000110465926016792/tm266493d1_8k.htm)

## Cash, going concern and the VCN-01 bet

Theriva's cushion is thin. It held about $11.3 million in cash and cash equivalents on June 30, 2026, and $9.6 million in early August. Operations used $5.5 million in the first six months of 2026, the accumulated deficit reached $364 million, and working capital stood at $1.6 million. Management reported substantial doubt about the company's ability to continue as a going concern and expected cash to last into the first quarter of 2027. A deferred $5.0 million payment owed to Grifols Innovation and New Technologies Limited, which the filing says would significantly deplete cash, is still under discussion. [August 11 quarterly filing](https://www.sec.gov/Archives/edgar/data/894158/000110465926093786/tmb-20260630x10q.htm)

With ribaxamase gone, the lead candidate is VCN-01, an oncolytic adenovirus. The company describes a "successful Phase 2b" in first-line metastatic pancreatic cancer; its quarterly filing says the 112-patient VIRAGE trial met its primary endpoints and that the FDA gave general agreement in March to a proposed Phase 3 design. VIRAGE2, a small proof-of-concept study of more frequent dosing, dosed its first patient on August 6; Theriva expects enrollment to finish in H2 2026 and initial pharmacodynamic and safety data by Q3 2027, after the period its current cash is expected to cover. [November 2 release](https://www.sec.gov/Archives/edgar/data/894158/000110465926121318/tm2628598d1_ex99-1.htm) · [August 6 filing](https://www.sec.gov/Archives/edgar/data/894158/000110465926091674/tm2622359d1_8k.htm) · [August 11 quarterly filing](https://www.sec.gov/Archives/edgar/data/894158/000110465926093786/tmb-20260630x10q.htm)

Shareholders vote on November 18 on raising authorized common stock from 350,000,000 to 500,000,000 shares and on ratifying the 2026 annual meeting's approval of issuing up to 16,184,560 shares on exercise of warrants from a private placement that closed on October 17, 2025. The proxy lists 45,892,668 shares outstanding as of the October 9 record date and 16,339,060 shares issuable under outstanding warrants. Earlier special meetings in February, April and June failed to reach a quorum. Shelf registration sales are limited until the market value of shares held by non-affiliates reaches $75 million. [October 20 proxy](https://www.sec.gov/Archives/edgar/data/894158/000110465926117417/tm2627846d1_def14a.htm) · [February 12 filing](https://www.sec.gov/Archives/edgar/data/894158/000110465926013907/tm266134d1_8k.htm) · [April 9 filing](https://www.sec.gov/Archives/edgar/data/894158/000110465926041507/tm2611468d1_8k.htm) · [June 5 filing](https://www.sec.gov/Archives/edgar/data/894158/000110465926070966/tm2616886d1_8k.htm) · [August 11 quarterly filing](https://www.sec.gov/Archives/edgar/data/894158/000110465926093786/tmb-20260630x10q.htm)

Sources

- https://www.sec.gov/Archives/edgar/data/894158/000110465926121318/tm2628598d1_ex99-1.htm
- https://www.sec.gov/Archives/edgar/data/894158/000110465926121318/tm2628598d1_8k.htm
- https://www.sec.gov/Archives/edgar/data/894158/000110465926121318/tm2628598d1_ex10-1.htm
- https://www.sec.gov/Archives/edgar/data/894158/000110465926093786/tmb-20260630x10q.htm
- https://www.sec.gov/Archives/edgar/data/894158/000110465926016792/tm266493d1_8k.htm
- https://www.sec.gov/Archives/edgar/data/894158/000110465926091674/tm2622359d1_8k.htm
- https://www.sec.gov/Archives/edgar/data/894158/000110465926117417/tm2627846d1_def14a.htm
- https://www.sec.gov/Archives/edgar/data/894158/000110465926013907/tm266134d1_8k.htm
- https://www.sec.gov/Archives/edgar/data/894158/000110465926041507/tm2611468d1_8k.htm
- https://www.sec.gov/Archives/edgar/data/894158/000110465926070966/tm2616886d1_8k.htm
